Provenienza dei contatti di primo grado di Nicholas Higgins
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
Intercytex Ltd.
 Intercytex Ltd. Pharmaceuticals: MajorHealth Technology The company is developing cell-based treatments for skin and hair regeneration. Its TrichoCyte product candidate is injected just beneath the scalp to encourage new hair follicles to form. Another product candidate, ProtoDerm, could treat diabetic ulcers and other chronic dermal wounds.
3
| Extinct | Pharmaceuticals: Major | 3 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Nicholas Higgins tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
Organogenesis, Inc.
 Organogenesis, Inc. Medical SpecialtiesHealth Technology Organogenesis, Inc. designs and manufactures regenerative medical products. It offers Apligraf, a living cell-based product indicated for the treatment of venous leg ulcers and diabetic foot ulcers and Dermagraft, a product for the treatment of diabetic foot ulcers. The firm also provides bioactive wound healing, biosurgery, and aesthetic medicine containing living cells and natural connective tissues. The company was founded in 1985 and is headquartered in Canton, MA. | Medical Specialties | Corporate Officer/Principal | |
| The University of Exeter | College/University | Undergraduate Degree | |
| RENEURON GROUP PLC | Pharmaceuticals: Major | Director of Finance/CFO | |
| THERACRYF PLC | Medical/Nursing Services | Director of Finance/CFO | |
TC Biopharm Ltd.
 TC Biopharm Ltd. Miscellaneous Commercial ServicesCommercial Services TC Biopharm Ltd. provides research services. The firm specializes in clinical grade cell therapy, cancer immonotherapy, regenerative medicine, and stratified medicine. The company was founded by Michael Leek, Angela Scott and David Galagher in 2014 and is headquartered in Edinburgh, the United Kingdom. | Miscellaneous Commercial Services | Chief Executive Officer | |
| TC BIOPHARM (HOLDINGS) PLC | Biotechnology | Chief Executive Officer | |
TCB Newco Ltd.
 TCB Newco Ltd. Pharmaceuticals: MajorHealth Technology TCB Newco Ltd. provides clinical services. It develops CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease. The company was founded on July 5, 2021 and is headquartered in Motherwell, GB. | Pharmaceuticals: Major | Chief Executive Officer | |
| University of Leeds | College/University | Doctorate Degree |
Statistiche
Distribuzione geografica
| Regno Unito | 11 |
| Stati Uniti | 2 |
Settori
| Health Technology | 6 |
| Commercial Services | 3 |
| Consumer Services | 3 |
| Industrial Services | 2 |
| Health Services | 2 |
Posizioni
| Director of Finance/CFO | 5 |
| Chief Executive Officer | 4 |
| Founder | 4 |
| Chief Tech/Sci/R&D Officer | 3 |
| Chairman | 3 |
Contatti più connessi
| Insiders | |
|---|---|
| Richard Moulson | 6 |
| Michael Leek | 5 |
| Paul Kemp | 4 |
- Borsa valori
- Insiders
- Nicholas Higgins
- Connessioni Società
